Added 4 days ago Drug news

Motif Bio plc completes rolling submission to FDA for iclaprim for the treatment of acute bacterial skin and skin structure infections (ABSSSI).

Motif Bio plc has announced the completion of its rolling submission of a New Drug Application (NDA) to the FDA...

Added 6 days ago Drug news

Pooled data from REVIVE-1 and REVIVE-2 trials of iclaprim in ABSSSI patients confirms non inferiority to vancomycin.- Motif Bio plc.

Motif Bio plc has announced that the pooled efficacy and safety data from its two Phase III trials (REVIVE-1 and...

Added 6 days ago Drug news

Post-hoc analysis of IGNITE1 and IGNITE4 trials of eravacycline met endpoints in complicated intra-abdominal infections.- Tetraphase Pharma.

Tetraphase Pharmaceuticals recently reported data on eravacycline, which is currently under review by the FDA and the EMA for the...

Guidelines on Urological Infections

The European Association of Urology (EAU) Urological Infections Guidelines Panel has compiled these clinical guidelines to provide medical professionals with evidence-based information and recommendations for...

Added 2 years ago

The Prevention of Early-onset Neonatal Group B Streptococcal Disease

The purpose of this guideline is to provide guidance for obstetricians, midwives and neonatologists on the prevention of early-onset (less than 7 days of age) neonatal group B streptococcal (EOGBS) disease...

Added 5 years ago

Fever in under 5s: assessment and initial management

This guideline covers the assessment and early management of fever with no obvious cause in children aged under 5.

Added 5 years ago

Pseudomonas aeruginosa in cystic fibrosis patients with c.1652G›A (G551D)-CFTR treated with ivacaftor-Changes in microbiological parameters.

The CFTR potentiator, ivacaftor (IVA), has been widely used in the treatment of cystic fibrosis (CF) patients with the G551D mutation. To date, there has been limited information on the microbiological status...

Added 4 months ago

Early goal-directed therapy in the treatment of severe sepsis and septic shock.

Goal-directed therapy has been used for severe sepsis and septic shock in the intensive care unit.

Added 1 year ago

Early, goal-directed therapy for septic shock – a patient-level meta-analysis.

After a single-center trial and observational studies suggesting that early, goal-directed therapy (EGDT) reduced mortality from septicshock, three multicenter trials (ProCESS, ARISE, and ProMISe) showed no benefit.

Added 1 year ago